|Bid||112.61 x 900|
|Ask||112.80 x 900|
|Day's range||110.82 - 113.72|
|52-week range||104.63 - 142.60|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||26.29|
|Forward dividend & yield||1.88 (1.66%)|
|Ex-dividend date||13 Apr 2022|
|1y target est||N/A|
(Bloomberg) -- As a nationwide baby formula shortage sends parents into crisis mode, social media posts containing dangerous misinformation about homemade formula recipes have gone viral online, racking up views in the millions. Although major networks like Facebook, TikTok and YouTube have taken steps to label photos, videos and posts with contextual information pointing to the harms of such recipes, and in some cases removed them, they have done so inconsistently, allowing the advice to contin
With the nation's shelves looking a bit too thin on baby formula products, Abbott Laboratories (NYSE: ABT) is in the hot seat. After voluntarily starting a recall of several of its baby formulas due to dangerous contamination issues in February, a national shortage quickly developed, as the Michigan-based factory operated by the company was one of the country's major suppliers of formula. A nonstop flurry of headlines implicates Abbott Labs in a quickly escalating scandal.
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.